Pharma Stock Below Rs 50 Trading In Green As Subsidiary Partners With Respilon Group

Sigachi Industries Limited, a major player in the pharma and nutraceutical industry, announced a strategic collaboration after signing a Memorandum of Understanding (MoU) between its subsidiary Sigachi MENA FZCO and Respilon Group s.r.o. The aim of the collaboration is to advance nanofiber-based drug delivery technologies.

In Sigachi's most recent exchange filing, the company stated that it intends to leverage Respilon's patented nanofiber technology in the development of non-invasive precision drug delivery devices aimed at improving therapeutic outcomes and patient care.
"Aligning perfectly with our vision to deliver next-generation pharmaceutical solutions that escalate therapeutic outcomes and enhance the patient experience, partnering with Respilon fuels our expectations around how NUENEX for drug delivery systems can globally revolutionize them," said Amit Raj Sinha, Managing Director and CEO of Sigachi Industries.

The partnership will not only address the creation of new APIs and drug delivery systems using nanofiber encapsulation methods but also the commercialization of active pharmaceutical ingredients (APIs) and formulations as part of the complex. Underneath the strategic alliance, this partnership will allow Sigachi to further expand its innovative leads in the pharmaceutical space targeted at the patients in need.

After the announcement, Sigachi Industries shares have positively reacted and reached a supersession value of Rs 43.93 on Monday, gaining 5.09% from the day's low of Rs 41.80. The stock has provided a staggering 22.91% return to investors in the last one month, garnering strong momentum from Rs 34.51 (its 52-week low) marked in February 2025. The stock also had a recorded 52-week high of Rs 75.45 on the 27th of May 2025.

Additionally, Sigachi Industries has reported fulfilling financial results for the third quarter and nine-months period ending in FY25. Revenue for Q3FY25 stands at Rs 139.42 crores, which is a 26% increase and EBITDA is Rs 35.19 crores, showing a 45% increase. Their lagging net profit also rose 33% year on year, reaching Rs 21.35 crores. For 9MFY25, the revenue sits at Rs 360.03 crores, which depicts a 22% growth alongside an EBITDA growth of 39%, sitting at Rs 89.75 crores and a consolidated profit after tax (PAT) of Rs 56.29 crores, depicting a 33% surge compared to the previous year.

For over the past 35 years, Sigachi Industries has been publicly traded on NSE and BSE, and it has emerged as an international leader in manufacturing advanced excipients, Vitamin-Mineral nutrient blends, API's, and providing operational as well as maintenance services related to them. The company specializes in blending, encapsulation, and spray drying, which helps in the innovation of food stability and fortification solutions.

Strategically positioned at the intersection of various industrial sectors, Sigachi has emerged as a preferred innovative solution provider for nutraceutical, pharmaceutical, and food companies around the world. With Respilon Group as its latest partner, Sigachi Industries cements its drive to propel innovative pharmaceutical development and enhance healthcare around the globe.